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ABSTRACT  
Hepatitis C virus (HCV) is a major cause of chronic liver disease resulting in cirrhosis and hepatocarcinoma. It is 
believed to be widespread in Africa but its epidemiology is incomplete and is yet to be determined in many areas 
of the sub-saharan Africa including Nigeria. Using third generation enzyme immuno-assay (EIA-3) and 
recombinant immunoblot assay (RIBA) technique as confirmatory test, we examined the prevalence of HCV 
antibodies in 226 blood donors and 226 patients attending Aminu Kano Teaching Hospital (AKTH) in Kano, 
Nigeria and evaluated the risk factors of HCV transmission in this environment. HCV antibodies were detected 
in 0.4% and 2.2% blood donors and patients respectively. The overall HCV seroprevalence was 1.3%. There was 
increased infection acquisition with increasing age; one (16.7%) HCV infection occurred in 25-34 years age group 
and 5 or 83.3% in subjects > 45 years in age which was significant (P< 0.05). The ratio of infection in male to 
female was 1:5. Evidence of previous exposure via transfusion was common in HCV seropositive subjects and 
could be a major risk factor of acquisition in this environment. Adequate screening of blood products in sub-
Saharan Africa (Nigeria inclusive) may minimize the risk of HCV transmission and associated health 
complications.  
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INTRODUCTION  
Hepatitis C Virus (HCV) is an enveloped, single-
stranded, positive sense RNA virus. It is a member of 
flaviviridae family placed in genus, hepacivirus (1, 2). 
It is an important  
cause of liver disease in the tropics; provoking 
chronic persistent infection progressively causing 
chronic hepatitis leading to liver cirrhosis and 
hepatocarcinoma (HCC) (3,5).  
As at 1997, the World Health Organization (WHO)(6) 
estimated that about 170 million people were chronic 
carriers of HCV infection worldwide. Furthermore, 
an average of 14% of infected persons was at risk of 
developing liver  
 
cirrhosis, HCC or both annually. There are about 3.2-
4 million cases of chronic HCV in the United States 
(US) alone which results in at least 10,000 deaths each 
year (7,8). In Canada, the number of HCV cases was 
estimated to be as high as 270,000 (9). 
Routes of HCV transmission include parenteral 
(including illicit drug abuse by injection), sexual, 
vertical (from mother to child) and through blood 
transfusion while tattooing and all forms of 
circumcision (ritual or traditional) have been 
suggested as modes of acquisition of the disease (10-
13).  
Data from various epidemiological studies globally 
indicated that HCV seroprevalence among the 
general population varies from < 1 % to 2% in 
industrialized countries of the west (14) and >20% in 
certain regions of Africa (15) and south-east Asia (16). 
However, among the blood donors, the HCV 
seroprevalence was 1.4% in the US, 0.5-1 %in the 
United Kingdom (UK) and 0.68% in France (17). In 
sub-saharan Africa (Nigeria inclusive), there is 
paucity of data on HCV infection while a few studies 
carried out in Nigeria were mainly from the southern 
part of the country, and none from our hospital 
location in Kano; a commercial centre in the north-
west geopolitical zone of Nigeria. The study was 
therefore aimed 'to determine the seroprevalence of 
HCV among blood donors and patients attending 
Aminu Kano Teaching Hospital (AKTH), a tertiary 
health centre in Kana, Nigeria and evaluate the risk 
factors of HCV acquisition in this environment.  
SUBJECTS, MATERIALS AND METHODS  
The subjects screened for HCV antibodies comprised 
of 226 (215 males and 15 females) asymptomatic 
blood donors consecutively recruited for testing. 
Others were 226 (95 males and 127 females) patients 
from the general outpatient Department (GOPD) of 
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the hospital who were randomly selected for the 
study. In total, there were 310 or 68.6% males and 142 
(31.4%) females. Their ages ranged from 15 to 59 
years (median 37.5 years). Using a structured 
questionnaire and with informed consent, all the 
participants were interviewed to record history of 
surgery, blood transfusion, tattooing, use of illicit 
drugs like cocaine or heroin by injection, known 
previous infectious diseases, anaemia etc. All 
individuals who reported for blood re-donation for 
the blood bank during the investigation and the 
immunocompromised were excluded from the study. 
The study was conducted between February and 
August, 2007 and was approved by ethnical 
committee of the hospital.  
 
TABLE 1: HCV ANTIBODY TEST RESULTS   
                 OF SUBJECTS AT AKTH 
Subjects       No screened     No positive (%) 
Patients     226   5 (2.2)  
Blood donors  226   1 (0.4)  
Total   452   6(1.3) 
Serological assay  
Serum samples were obtained by standard methods 
and tested for HCV antibodies. Briefly, 5 millilitres of 
blood was collected from each subject by venous 
puncture and centrifuged at 3000rpm for 5 minutes. 
Serum was separated from each blood sample and 
stored at - 20°C until analyzed. The sera were tested 
for anti-HCV antibodies by employing third 
generation enzyme immuno-assay technique 
(Caltech. Diagn. Incorp. Cal. USA). For assurance, all 
positively reactive samples from the initial test were 
retested with recombinant immunoblot assay (RIBA) 
or, western blot, (Diasorin, Italy) for confirmation. 
Testing Procedures and interpretation of results were 
as prescribed by the manufactures of test kits. These 
were methodically followed and strictly adhered to. 
All positive patients were informed of the test results 
for further medical evaluation and management. Data 
were analysed using simple proportion student’s t-
test or Wilcoxon signed rank was used to compare 
continuous variables and the chi-square test was used 
to compared proportions. A p value of < 0.05 was 
considered significant.  
RESULTS  
The HCV diagnosis of the participants comprising 
blood donors and patients attending AKTH in Kano, 
Nigeria is shown in table 1. The overall HCV 
seroprevalence was 1.3% consisting of 2.2% and 0.4% 
seropositive patients and blood donors respectively. 
Of 452 subjects screened for HCV infection, 310 
(68.6%) were males and 142 or 31.4% were females. The 
ages of patients ranged from 15-59 years (mean + SD, 
39.5 + 3.5) while ages of the blood donors ranged 
from 18-49 (mean ± SD, 35.2 ± 4.1) (Table 2).  
 
TABLE 2: SEX AND AGE RANGE OF PATIENTS 
AND BLOOD DONORS SCREENED 
FOR HCV ANTIBODY AT AKTH 
 
Subjects       No screened      Age range (yr.)  
      (Male/female)      Mean + SD 
Patients        226 (95/127)      15 – 59 (39.5 + 3.5) 
]Total (%)      452(310)            (68.6)/142 (31.4) 
 
The distribution of HCV seropositivity according to 
age range, sex and history of transfusion is shown in 
table 3. Out of 6 HCV seropositive subjects, 5 or 83.3% 
were females with all of them having history of blood 
transfusion and was found to be statistically 
significant (P<0.05) while the remaining one was a 
male who did not have any record of transfusion. 
However, the possible source or route of acquisition 
in this male subject could not be ascertained.  
 
TABLE 3: HCV SEROPOSITIVITY OF SUBJECTS  
ACCORDING TO SEX AND HISTORY OF 
TRANSFUSION  
 
Age range of       No          sex       No (% with history  
Subjects (yr.)   (% +ve)   M    F     of transfusion) 
15 – 24                -             -       -               - 
25 – 34                1(6.7)     1       -               1  
35 – 44                 -            -        -             -  
> 45                    5(83.3)   1      4                4   
Total (%)             6      1(16.7)  5(83.3) 5(83.3) 
 
There was increased infection acquisition with 
increasing age; five seropositive subjects were > 45 
years in age which was significant (P<0.05) while the 
remaining female subject was 27 years old.  
DISCUSSION  
In this study, the overall prevalence of HCV infection 
was found to be 1.3% comprising blood donors and 
patients attending our hospital (AKTH) in Kano, 
Nigeria. This prevalence is low compared with the 
rates reported elsewhere in the country viz: among 
some selected risk groups including 37.9% in patients 
attending STD clinics (18), 18.7% among patients with 
HCC (19) and 14% among blood donors and patients 
attending sickle-cell anaemia clinics (20) in Nigeria. 
The variations may be due to difference in study 
populations, and rate of exposure to risk factors of 
HCV transmission in those areas. However, this 
figure of 1.3% falls within the published data of 0.4 - 
1.5% seroprevalence from Western Europe and North 
America (17) and corroborates the level of infection 
rate of HCV in those areas.  
 
The prevalence of HCV infection in our study was 
0.4% among blood donors and 2.2% among hospital 
patients. These results were consistent with the 
estimates of 0.3 - 1 among blood donors in Europe 
and Australia, (11) and 1-2.4% reported from parts of 
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Asia including Pakistan, India, China and Bangladesh 
(21). These prevalence rates were however, lower 
than 4% - 12.5% of HCV infection published from 
various regions of Africa (22), and as high as 47% 
reported in parts of Nigeria (23,24).  The wide 
disparity in HCV prevalence may be due to profound 
diversity in demographic characters of populations 
and subpopulations in this continent. Moreso, the 
issue of quality and reliability of HCV infection 
diagnosis especially in poor-resourced developing 
economics due to inadequate facility and high cost of 
test kits may play a role in the present scenario (22).  
 
The incidence of HCV infection was correlated with 
increasing age (one case in 25-34 years age range; 5 
cases in > 45 years age) and was significantly (P<0.05) 
higher in females than males by ratio 5:1. The 
scenario corroborates the report of Halim and 
Ajayi(23) who suggested that age could be a 
contributing risk factor in the acquisition of HCV 
infection especially in endemic areas. Similarly, the 
reason for increased rate of infection in females than 
their male counterparts may be explained by 
tendency of exposure to multiple risk factors in 
depressed economy with inadequate health care 
system in a country like Nigeria. These include 
variety of poorly conducted surgery-assisted 
treatments for gynaecological problems which may 
require blood transfusion. For instance, evidence of 
previous exposure to HCV through caesarian 
operation (CS) and transfusion (conducted outside of 
our hospital) during child delivery was given by 5 
(83.3%) female subjects all of whom were HCV 
positive; a finding that is statistically significant (P < 
0.05). This outlook corroborates the hypothesis that 
transfusion is a major risk factor in the transmission 
of HCV especially in poor-resourced areas of the 
developing world. In view of this outcome, it is 
imperative that adequate screening of blood and 
blood products for HCV be carried out in all blood 
transfusions to minimize the risk of HCV 
transmission in sub-Saharan Africa including 
Nigeria. There is need to provide necessary facility in 
this regard that will aid HCV control measures and 
prevent associated health complications.  
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